


**REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14**

Bring completed form to:  
File Information Unit  
Crystal Plaza Three, Room 1D01  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 306-2733



In re Application of

Application Number

Filed

09/426,814

10/22/99

Paper No.

10

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_.

United States Patent Number 2005 000295 column \_\_\_\_\_, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

**Related Information about Access to Pending Applications (37 CFR 1.14):**

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:  
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

**For unpublished applications that are still pending:**

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the file contents;
  - the pending application as originally filed; or
  - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the pending application as originally filed.

Signature

Date

Typed or printed name

Registration Number, if applicable

Telephone Number

FOR PTO-USE-ONLY	
RECEIVED	
Approved by: <u>A to</u>	(initials)
File Information Unit	



US 20050002959A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0002959 A1**  
**Holmes et al.** (43) **Pub. Date: Jan. 6, 2005**

(54) **RECOMBINANT IL4 ANTIBODIES USEFUL  
IN TREATMENT OF IL4 MEDIATED  
DISORDERS**

(75) **Inventors: Stephen Dudley Holmes, Epsom (GB);  
Mitchell Stuart Gross, Wayne, PA  
(US); Daniel R. Sylvester,  
Phoenixville, PA (US)**

**Correspondence Address:**

**GLAXOSMITHKLINE**

**Corporate Intellectual Property - UW2220**

**P.O. Box 1539**

**King of Prussia, PA 19406-0939 (US)**

(73) **Assignees: SmithKline Beecham p.l.c.; SmithKline  
Beecham Corporation**

(21) **Appl. No.: 10/723,872**

(22) **Filed: Nov. 26, 2003**

**Related U.S. Application Data**

(63) Continuation of application No. 09/879,461, filed on Jun. 12, 2001, now abandoned, which is a continuation of application No. 09/426,814, filed on Oct. 22, 1999, now abandoned, which is a continuation of application No. 08/612,929, filed on Apr. 30, 1996, now abandoned, filed as 371 of international application No. PCT/US94/10308, filed on Sep. 7, 1994, which is a continuation-in-part of application No. 08/136,783, filed on Oct. 14, 1993, now abandoned, which is a continuation of application No. 08/117,366, filed on Sep. 7, 1993, now abandoned.

**Publication Classification**

(51) **Int. Cl.<sup>7</sup> ..... A61K 39/00; C12P 21/04;  
C07K 16/46**  
(52) **U.S. Cl. .... 424/192.1; 435/69.7; 530/350;  
530/391.1**

(57) **ABSTRACT**

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.